Paula Morales

The paper shows a bivalent ligand enhances CB2R homodimerization, leading to increased Gi binding potency and β-arrestin recruitment.

This study identifies CB1R overactivation as a driver of CRBN deficiency-linked ARNSID and suggests CB1R blockade as a potential therapy.